Tonix Pharmaceuticals Holding (TNXP) Operating Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Operating Expenses for 16 years, with the latest figure at $56.1 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 85.12% year-over-year to $56.1 million in Q2 2026; TTM through Jun 2026 was $194.5 million, a 110.95% increase from a year earlier, with the FY2025 full-year figure at $138.8 million, down 5.44% from the prior year.
• Operating Expenses was $56.1 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $48.4 million in the prior quarter.
• The five-year high for Operating Expenses was $79.5 million in Q2 2024, with the low at $18.4 million in Q3 2024.
• Average Operating Expenses over 5 years is $34.9 million, with a median of $30.7 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 174.2% in 2024, then slumped 61.91% in 2025.
• Over 5 years, Operating Expenses stood at $32.7 million in 2022, then fell by 4.95% to $31.1 million in 2023, then dropped by 19.44% to $25.1 million in 2024, then surged by 114.17% to $53.7 million in 2025, then climbed by 4.48% to $56.1 million in 2026.
• The last three Operating Expenses figures came in at $56.1 million (Q2 2026), $48.4 million (Q1 2026), and $53.7 million (Q4 2025), per Business Quant data.